Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/05/18
End: 12/15/21
Due: 12/15/22
Phase: N/A
Priority: Normal
Start: 03/27/17
End: 02/25/22
Due: 02/25/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | NCT03655613 | Apollomics (Australia) Pty. Ltd. | user2@example.com | None | 2018-09-05 | 2021-12-15 | 2022-12-15 | - | - | 2025-07-14 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | NCT03053466 | Apollomics (Australia) Pty. Ltd. | user2@example.com | None | 2017-03-27 | 2022-02-25 | 2023-02-25 | - | - | 2025-07-14 |